Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bausch + Lomb Corporation Common Shares (NY: BLCO )

17.65 UNCHANGED
Streaming Delayed Price Updated: 11:13 AM EST, Jan 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 Next >
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Responds to Rumors of a Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Third-Quarter 2024 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden. 
Via MarketBeat
Bausch + Lomb Announces Second-Quarter 2024 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31
From Bausch + Lomb Corporation
Via Business Wire
Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces First-Quarter 2024 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors
From Bausch + Lomb Corporation
Via Business Wire
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
From Emergent BioSolutions
Via GlobeNewswire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.